Double Epigenetic Modulation of High-Dose Chemotherapy With Azacitidine and Vorinostat for Patients With Refractory or Poor-Risk Relapsed Lymphoma

BACKGROUND: More active high-dose chemotherapy (HDC) regimens are needed for refractory lymphomas. The authors previously combined infusional gemcitabine with busulfan and melphalan (Gem/Bu/Mel) pursuing DNA damage repair inhibition. Subsequently, they combined Gem/Bu/Mel with vorinostat, which faci...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer
Asıl Yazarlar: Nieto, Yago, Valdez, Benigno C., Thall, Peter F., Jones, Roy B., Wei, Wei, Myers, Alan, Hosing, Chitra, Ahmed, Sairah, Popat, Uday, Shpall, Elizabeth J., Qazilbash, Muzaffar, Gulbis, Alison, Anderlini, Paolo, Shah, Nina, Bashir, Qaiser, Alousi, Amin, Oki, Yasuhiro, Fanale, Michelle, Dabaja, Bouthaina, Pinnix, Chelsea, Champlin, Richard, Andersson, Borje S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4992444/
https://ncbi.nlm.nih.gov/pubmed/27203405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30100
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller